- PROFESSOR Population Health Science and Policy
- PROFESSOR Medicine
- Dr. Moskowitz is Co-director of the International Center for Health Outcomes and Innovation Research (InCHOIR), with over 15 years of experience in directing both clinical and data coordinating centers for multicenter clinical trials, both NIH and industry sponsored. He has expertise in designing clinical trials, and overseeing the development of web-based data collection instruments, data management, study monitoring, committee management, interim and final analysis and publication of results. In addition to such traditional endpoints as survival he has expertise with health resource use, quality of life, patient preferences, and functional status. Among other NIH supported clinical trials, he previously directed the clinical coordinating center for the REMATCH trial (left ventricular assist devices (LVAD) as a “destination therapy – 20 clinical centers). In addition to survival, quality of life and patient preferences were key endpoints for this trial. He has also co-directed the DCC for an NHLBI SCCOR project on LVADs and heart failure (12 clinical centers), which conducted multicenter observational and interventional studies related to infection, consumptive coagulopathy and cell therapy for cardiac regeneration. He currently directs the data coordinating center for the NINDS sponsored ARUBA trial (70 clinical centers worldwide) comparing watchful waiting to immediate intervention for patients with unruptured brain AVMS.
Dr. Moskowitz has been in the leadership team for the NHLBI support Cardiothoracic Surgical Trials Network (CTSN) to which he brings expertise in design and analysis of cardiac and neurological trials, functional status, quality of life and economic endpoints. He oversees the adverse event review process and the Biorepository, including the development of a mechanistic study research agenda.
Mohr JP, Moskowitz AJ, Parides M, Stapf C, Young WL. Hull Down on the Horizon: A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) Trial. Stroke 2012 Jun 5;(Epub ahead of print).
Perrault LP, Moskowitz AJ, Kron IL MD, Acker MA, Miller MA, Horvath KA, Thourani VH, Argenziano M, D’Alessandr DA, Blackstone EH, Moy CS, Mathew MD, Hung J, Gardner TJ, Parides MK. Optimal Surgical Management of Severe Ischemic Mitral Regurgitation: To Repair or to Replace? . J Thorac Cardiovasc Surg 2012 Jun; 143(6): 1396-403.Epub 2011 Nov 4.
Frontera JA, Egorova N, Moskowitz AJ. National trend in prevalence, cost, and discharge disposition after subdural hematoma from 1998-2007. Crit Care Med 2011 Jul; 39(7): 1619-25.
Mohr JP, Moskowitz AJ, Stapf C, Hartmann A, Weinberg A, Young WL, Estevez A, Kureshi I, Brisman JL. The ARUBA trial: current status, future hopes. Stroke 2010 Aug; 41(8).
Egorova NN, Gelijns AC, Moskowitz AJ, Emond JC, Krapf R, Lazar EJ, Guillerme S, Kaplan HS, Greco G. Process of care events in transplantation: effects on the cost of hospitalization. Am J Transplant 2010 Oct; 10(10): 2341-8. doi: 10.1111/j.1600-6143.2010.03260.x.Epub 2010 Sep 14.
Gelijns AC, Ascheim DD, Parides MK, Kent KC, Moskowitz AJ. Randomized trials in surgery. Surgery 2009 Jun; 145(6): 581-7.
Parides MK, Moskowitz AJ, Ascheim DD, Rose EA, Gelijns AC. Progress versus precision: challenges in clinical trial design for left ventricular assist devices. Annals of Thoracic Surgery 2006 Sep; 82(3): 1140-6.
Gelijns AC, Brown LD, Magnell C, Ronchi E, Moskowitz AJ. Evidence, Politics, and Technological Change. Health Affairs 2005; 24(1): 29-40.
Oz MC, Gelijns AC, Miller L, Wang C, Nickens P, Arons RR, Aaronson K, Richenbacher W, van Meter C, Nelson K, Weinberg A, Watson JT, Rose EA, Moskowitz AJ. Left Ventricular Assist Devices as Permanent Heart Failure Therapy: The Price of Progress. Annals of Surgery 2003 Oct; 238(4): 577-585.
Rose EA, Gelijns AC, Moskowitz AJ, et al . Long Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. The New England Journal of Medicine 2001 Nov; 345(20): 1435-1443.
Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. Annals of Thoracic Surgery 2001 Mar; 71(3 Suppl): S195-8.
Heitjan DF, Moskowitz AJ, Whang W. Bayesian Estimation Of Cost-Effectiveness Ratios From Clinical Trials. Health Economics 1999 May; 8(3): 191-202.
Whang W, Sisk JE, Heitjan DF, Moskowitz AJ. Probabilistic sensitivity analysis in cost-effectiveness: An application from a study of vaccination against pneumococcal bacteremia in the elderly. Int J Technol Assess Health Care 1999; 15(3): 563-572.
Gelijns AC, Rosenberg N, Moskowitz AJ. Capturing the Unexpected Benefits of Medical Research. The New England Journal of Medicine 1998 Sep; 339(10): 693-8.
Sisk JE, Moskowitz AJ, Whang W, et al . Cost-Effectiveness of Vaccination Against Pneumococcal Bacteremia Among Elderly People. JAMA 1997; 278(16): 1333-1339.
- Surgical Interventions for Moderate Ischemic Mitral Regurgitation
- A Randomized Multicenter Clinical Trial of Unruptured Brain Arteriovenous malformations (ARUBA)
- A Randomized Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Implantation of Left Ventricular Assist Devices
- An Observational, ex vivo Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Warfarin Therapy
- Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Moskowitz during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- MERS International, LLC
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Icahn (East) Building Floor 2nd Floor Room L2-44
1425 Madison Avenue
New York, NY 10029